How long does it take for resistance to Osimertinib (Tagressa) to develop? How to deal with drug resistance?

As a targeted therapy, Osimertinib is widely used to treat EGFR (epidermal growth factor receptor) mutation-positive advanced non-small cell lung cancer (NSCLC). Although osimertinib has shown significant efficacy in treatment, patients may develop drug resistance during treatment. The following are the factors affecting osimertinib resistance, resistance mechanisms and treatment strategies after resistance:

1.Factors affecting drug resistance:

EGFR mutations: One of the most common resistance mechanisms in patients with NSCLC treated with osimertinib is novel EGFR mutations. For example, the EGFR T790M mutation is a common drug-resistant mutation that renders tumor cells less sensitive to osimertinib.

Immune evasion: Another mechanism leading to drug resistance is immune evasion of tumor cells. Tumor cells can evade immune surveillance and clearance by changing the expression levels of their immune-related genes, thereby reducing sensitivity to osimertinib.

Activation of other pathways: Some studies have shown that activation of other cell signaling pathways during osimertinib treatment may also lead to the development of drug resistance, for example, through activation of the PI3K/AKT/mTOR signaling pathway.

2.Resistance mechanism:

NewEGFRmutations: As mentioned previously, the EGFR T790M mutation is one of the most common resistance mechanisms during osimertinib treatment. This mutation renders EGFR less sensitive to osimertinib, allowing tumor cells to continue growing and spreading.

Other mechanisms: In addition to newEGFRIn addition to mutations, there are other mechanisms that lead to osimertinib resistance, such as METenhancement, KRASmutation, HER2amplification, etc. These mechanisms may lead to reduced sensitivity of tumor cells to osimertinib, thus limiting its therapeutic efficacy.

3.Treatment strategies after drug resistance:

Conduct resistance testing: Resistance testing should be considered when patients experience disease progression or clinical signs of resistance to identify mechanisms of resistance. This can help guide the selection of subsequent treatment options and optimize treatment strategies.

Looking for new treatment options: Once a patient develops resistance to osimertinib, it is necessary to consider switching or combining other treatment options. Depending on the results of the drug resistance test and the specific situation of the patient, other targeted therapy drugs, immunotherapy, chemotherapy and other options can be considered.

Participation in clinical trials: For patients with drug-resistantNSCLC, participation in clinical trials is an important choice. Clinical trials may provide new treatment strategies or targeted drugs and help find more effective treatments.

Comprehensive treatment strategy: When formulating treatment plans, comprehensive treatment strategies should be considered, including the combination of surgery, radiotherapy, chemotherapy, targeted therapy and other treatment methods, in order to maximize the patient's survival and improve their quality of life.

4.Strategies to prevent drug resistance:

Regular monitoring: For NSCLC patients receiving osimertinib, regular clinical examinations and imaging evaluations should be performed, as well as monitoring of tumor marker levels in the blood. Early detection of signs of disease progression or drug resistance can help to adjust treatment plans in a timely manner.

Individualized treatment: Based on the patient's genotype, pathological characteristics, clinical conditions and other factors, individualized treatment options are selected, including rational drug selection, rational drug dosage and optimization of treatment plans.

Avoid inappropriate medication use: Avoid irrational medication use, such as overuse of antibiotics, hormones and other drugs, so as not to affect the treatment effect and lead to the development of drug resistance.

In general, osimertinib, as a targeted therapy, is very effective in the treatment ofEGFRmutation-positive late-stage patientsNSCLC showed significant efficacy in patients. However, patients may develop drug resistance while on treatment. Therefore, it is very important to promptly monitor the disease, identify resistance mechanisms, find new treatment options, and formulate individualized treatment strategies to improve patients' survival rate and quality of life.